The Korean journal of internal medicine

  • 제32권6호
  • /
  • Pages.947-958
  • /
  • 2017
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association

  • Ko, Seung-Hyun (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Hur, Kyu Yeon (Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Rhee, Sang Youl (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Kim, Nan-Hee (Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine) ;
  • Moon, Min Kyong (Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Park, Seok-O (Department of Internal Medicine, Gwangmyeong Sungae Hospital) ;
  • Lee, Byung-Wan (Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Hyun Jin (Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Choi, Kyung Mook (Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Jin Hwa (Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine) ;
  • Committee of Clinical Practice Guideline of Korean Diabetes Association (Korean Diabetes Association)
  • 투고 : 2017.08.25
  • 심사 : 2017.09.15
  • 발행 : 2017.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

키워드

참고문헌

  1. Ko SH, Kim SR, Kim DJ, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-436. https://doi.org/10.4093/dmj.2011.35.5.431
  2. Min KW, Ku BJ, Lee JH, et al. Addition of ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial. Diabetes Metab J 2017;41:135-145. https://doi.org/10.4093/dmj.2017.41.2.135
  3. Kim JH, Kim SS, Baek HS, et al. Comparison of vildagliptin and pioglitazone in Korean patients with type 2 diabetes inadequately controlled with metformin. Diabetes Metab J 2016;40:230-239. https://doi.org/10.4093/dmj.2016.40.3.230
  4. Yoon KH, Nishimura R, Lee J, et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Diabetes Obes Metab 2016;18:1045-1049. https://doi.org/10.1111/dom.12699
  5. Yoon KH, Hardy E, Han J. Exenatide versus insulin lispro added to basal insulin in a subgroup of Korean patients with type 2 diabetes mellitus. Diabetes Metab J 2017;41:69-74. https://doi.org/10.4093/dmj.2017.41.1.69
  6. American Diabetes Association. Standards of medical care in diabetes: 2017. Diabetes Care 2017;40(Suppl 1):S1-S135. https://doi.org/10.2337/dc17-S001
  7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
  8. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm: 2017 executive summary. Endocr Pract 2017;23:207-238. https://doi.org/10.4158/EP161682.CS
  9. McGuire H, Longson D, Adler A, Farmer A, Lewin I; Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ 2016;353:i1575.
  10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149. https://doi.org/10.2337/dc14-2441
  11. Kim JM, Hong JW, Noh JH, Kim DJ. Factors associated with participation in diabetes education: the Korea National Health and Nutrition Examination Survey 2007 to 2009. Diabetes Metab J 2016;40:447-453. https://doi.org/10.4093/dmj.2016.40.6.447
  12. Yong YM, Shin KM, Lee KM, et al. Intensive individualized reinforcement education is important for the prevention of hypoglycemia in patients with type 2 diabetes. Diabetes Metab J 2015;39:154-163. https://doi.org/10.4093/dmj.2015.39.2.154
  13. Ha KH, Kim DJ. Current status of managing diabetes mellitus in Korea. Korean J Intern Med 2016;31:845-850. https://doi.org/10.3904/kjim.2016.253
  14. Chon S, Gautier JF. An update on the effect of incretinbased therapies on ${\beta}$-cell function and mass. Diabetes Metab J 2016;40:99-114. https://doi.org/10.4093/dmj.2016.40.2.99
  15. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012. https://doi.org/10.1001/jama.281.21.2005
  16. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010;33:1859-1864. https://doi.org/10.2337/dc09-1727
  17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
  18. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-751. https://doi.org/10.7326/M15-2650
  19. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313-324. https://doi.org/10.1001/jama.2016.9400
  20. Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open 2014;4:e005442. https://doi.org/10.1136/bmjopen-2014-005442
  21. Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016;11:e0166125. https://doi.org/10.1371/journal.pone.0166125
  22. Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J 2016;40:423-432. https://doi.org/10.4093/dmj.2016.40.6.423
  23. Cha SA, Yun JS, Lim TS, et al. Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J 2016;40:202-210. https://doi.org/10.4093/dmj.2016.40.3.202
  24. Yoon KH, Shin JA, Kwon HS, et al. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011;35:26-33. https://doi.org/10.4093/dmj.2011.35.1.26
  25. Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis. Clin Invest Med 2016;39:E48-E62.
  26. Zhong X, Lai D, Ye Y, Yang X, Yu B, Huang Y. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol 2016;72:655-663. https://doi.org/10.1007/s00228-016-2010-8
  27. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378-388. https://doi.org/10.1016/j.diabres.2015.05.025
  28. Zhou JB, Bai L, Wang Y, Yang JK. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. Int J Clin Pract 2016;70:132-141. https://doi.org/10.1111/ijcp.12761
  29. Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17:581-590. https://doi.org/10.1111/dom.12459
  30. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708. https://doi.org/10.1007/s00125-012-2827-3
  31. Mearns ES, Saulsberry WJ, White CM, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med 2015;32:1530-1540. https://doi.org/10.1111/dme.12837
  32. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-2852. https://doi.org/10.1210/jc.2015-1884
  33. Oh S, Chon S, Ahn KJ, Jeong IK, Kim BJ, Kang JG. The role of glucagon-like peptide-1 receptor agonists in type 2 diabetes: understanding how data can inform clinical practice in Korea. Diabetes Metab J 2015;39:177-187. https://doi.org/10.4093/dmj.2015.39.3.177
  34. Kim MK, Suk JH, Kwon MJ, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011;92:322-328. https://doi.org/10.1016/j.diabres.2011.01.022
  35. Olansky L, Reasner C, Seck TL, et al. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab 2011;13:841-849. https://doi.org/10.1111/j.1463-1326.2011.01416.x
  36. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014;16:410-417. https://doi.org/10.1111/dom.12233
  37. Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitao C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016;13:e1001992. https://doi.org/10.1371/journal.pmed.1001992
  38. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322. https://doi.org/10.1056/NEJMoa1603827
  39. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. https://doi.org/10.1056/NEJMoa1504720
  40. Hwang YC, Kang JG, Ahn KJ, et al. The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(R) study. Int J Clin Pract 2014;68:1338-1344. https://doi.org/10.1111/ijcp.12482
  41. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-2632. https://doi.org/10.1161/01.CIR.99.20.2626
  42. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821-827. https://doi.org/10.1503/cmaj.090206
  43. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011;13:814-822. https://doi.org/10.1111/j.1463-1326.2011.01412.x
  44. Park CY, Kang JG, Chon S, et al. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One 2014;9:e87799. https://doi.org/10.1371/journal.pone.0087799
  45. Zhong X, Zhang T, Liu Y, et al. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: a network meta-analysis. Diabetes Res Clin Pract 2015;109:451-460. https://doi.org/10.1016/j.diabres.2015.05.048
  46. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD005613.
  47. Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 2015;25:898-905. https://doi.org/10.1016/j.numecd.2015.06.005
  48. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723-732. https://doi.org/10.1056/NEJMoa1615692
  49. Yki-Jarvinen H, Rosenstock J, Duran-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ${\geq}$52-week randomized, double-blind study. Diabetes Care 2013;36:3875-3881. https://doi.org/10.2337/dc12-2718
  50. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-257. https://doi.org/10.1111/dom.12020
  51. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012;14:795-802. https://doi.org/10.1111/j.1463-1326.2012.01600.x
  52. Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev 2017;33:e2818. https://doi.org/10.1002/dmrr.2818
  53. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2016;51:417-428. https://doi.org/10.1007/s12020-015-0718-3
  54. Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763-2773. https://doi.org/10.2337/dc14-0876
  55. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228-2234. https://doi.org/10.1016/S0140-6736(14)61335-0
  56. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16:636-644. https://doi.org/10.1111/dom.12262
  57. Choi SH, Oh TJ, Jang HC. Comparison of antidiabetic regimens in patients with type 2 diabetes uncontrolled by combination therapy of sulfonylurea and metformin: results of the MOHAS Disease Registry in Korea. Diabetes Metab J 2017;41:170-178. https://doi.org/10.4093/dmj.2017.41.3.170

피인용 문헌

  1. Development and validation of a risk prediction model for severe hypoglycemia in adult patients with type 2 diabetes: a nationwide population-based cohort study vol.10, pp.None, 2017, https://doi.org/10.2147/clep.s169835
  2. Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis vol.42, pp.2, 2018, https://doi.org/10.4093/dmj.2018.42.2.93
  3. Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes vol.120, pp.5, 2017, https://doi.org/10.1002/jcb.28141
  4. Management of type 2 diabetes using non‐insulin glucose‐lowering therapies: a critical appraisal of clinical practice guidelines with the AGREE II instrument vol.37, pp.4, 2017, https://doi.org/10.1111/dme.14231
  5. Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis o vol.37, pp.10, 2017, https://doi.org/10.1007/s12325-020-01471-2
  6. Associations Between Preoperative Glucose and Hemoglobin A1c Level and Myocardial Injury After Noncardiac Surgery vol.10, pp.7, 2021, https://doi.org/10.1161/jaha.120.019216
  7. Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes vol.42, pp.4, 2017, https://doi.org/10.4082/kjfm.19.0161
  8. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study vol.182, pp.None, 2021, https://doi.org/10.1016/j.diabres.2021.109123